Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02341326 · ClinicalTrials.gov registry record
Defective FGFR2 Signaling in the Small Airway Basal Progenitor Cells in COPD
A clinical trial, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- 111
- Enrollment target
NCT02341326 is a clinical trial that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 111 participants.
The verdict
NCT02341326 has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- 111 participants
- Enrollment target
Study Summary
Early changes associated with the development of smoking-induced diseases, e.g., COPD and lung cancer (the two commonest causes of death in U.S.) are often characterized by abnormal airway epithelial differentiation. Airway basal cells (BC) are stem/progenitor cells necessary for generation of differentiated airway epithelium. Based on our preliminary observations on SAE BC cells and FGFR2 signaling, we hypothesized that suppression of FGFR2 signaling in the SAE BC stem/progenitor cells by cigarette smoking renders these cells less potent in generating and maintaining normally differentiated SAE, shifting these cells towards a COPD associated phenotype. To test this, SAE basal cells will be isolated from cultured cells obtained through bronchoscopic brushings and analyzed through in vitro assays for their stem/progenitor capacities.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2014-07 |
| Est. Completion | 2024-10-29 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02341326
The ClinicalTrials.gov registry entry for NCT02341326 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02341326 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02341326 about?
NCT02341326 is a clinical study titled "Defective FGFR2 Signaling in the Small Airway Basal Progenitor Cells in COPD". Early changes associated with the development of smoking-induced diseases, e.g., COPD and lung cancer (the two commonest causes of death in U.S.) are often characterized by abnormal airway epithelial differentiation. Airway basal cells (BC) are stem/progenitor cells necessary for generation of diffe...
What is the current status of trial NCT02341326?
This trial is currently completed. The enrollment target is 111 participants. The study started on 2014-07. Estimated completion is 2024-10-29.
Who is sponsoring clinical trial NCT02341326?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.